Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $20.88.

TEVA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

Teva Pharmaceutical Industries Stock Up 1.5 %

Shares of TEVA opened at $21.20 on Thursday. The company has a market capitalization of $24.02 billion, a P/E ratio of -24.94, a PEG ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a one year low of $10.13 and a one year high of $21.98. The business’s 50 day simple moving average is $17.61 and its 200-day simple moving average is $17.45. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of TEVA. Envestnet Portfolio Solutions Inc. bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $188,000. Coronation Fund Managers Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $1,334,000. Raymond James & Associates lifted its holdings in Teva Pharmaceutical Industries by 5.1% during the second quarter. Raymond James & Associates now owns 815,944 shares of the company’s stock worth $13,259,000 after acquiring an additional 39,610 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Teva Pharmaceutical Industries by 69.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 62,410 shares of the company’s stock valued at $1,014,000 after acquiring an additional 25,657 shares during the period. Finally, Summit Securities Group LLC bought a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $366,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.